"中国协和医科大学流行病与卫生统计学博士，Johns Hopkins大学公共卫生学院遗传流行病学系博士后。先后作为课题或子课题负责人承担过科技部“十一五”、“十二五”、“十三五”传染病重大专项、国家自然科学基金、卫生部行业基金、教育部博士点基金新教师类、美国中华医学会、美国施贵宝基金会、吴阶平基金会等多项国家或国际级课题。以第一作者（或并列第一）、通讯作者（或并列通讯）在Nature genetics, Clinical Gastroenterology and Hepatology, Molecular Carcinogenesis, Hepatobiliary Surg Nutrition, Clinical nutrition等杂志发表多篇包括肝病在内的消化系统疾病等的高质量文章，目前在SCI收录的杂志中发表论文70余篇,其中第一作者或通讯作者50余篇。先后获中国协和医科大学中国医学科学院优秀博士论文奖，中华医学科技进步奖二等奖，教育部高等学校科学研究成果奖二等奖，北京市优秀人才资助等奖励。 "

围绕我国目前最重要的两大肝病，慢性乙型肝炎病毒（hepatitis B virus, HBV）感染及非酒精性脂肪性肝病（non-alcoholic fatty liver disease，NAFLD），明确慢性HBV感染与NAFLD的相互作用及对不良硬终点的影响，探索内外环境暴露与上述疾病及其不良结局发生机制；为实现对慢性HBV感染者及NAFLD的精准预防和治疗，降低不良结局的发生和死亡率提供适合我国国情的预防与控制策略。在上述研究基础上，开展基于电子病历数据库和人群队列的大数据挖掘的方法学探究。

过去3年作为通讯或共同通讯发表文章情况：（2020年-2022年8月，按时间顺序)

1.    Lan YQ, Lu Y, Li JF, Hu SQ, Chen SH, Wang YH, Yuan XJ, Liu HM, Wang XM, Wu SL, Wang L. Outcomes of lean, overweight or obese subjects with non-alcoholic fatty liver disease: a cohort study in China. Hepatology communication 2022 (Accepted)

2.    Yang H, ZhouRN, Bai XY, Guo MY, Ruan GC, Wang L*, Qian JM*. Trend and Geographic Variation in Incidence and Prevalence of Inflammatory Bowel Disease in Regions Across China: A Nationwide Employee Study Between 2013 and 2016. Front Med 2022, doi: 10.3389/fmed.2022.900251. eCollection 2022

3.    Hu SQ, Li XL, Sun YY, Wu SL, Lan YQ, Chen SH, Wang YH, Liao W, Wang XM, Zhang D, Yuan XJ, Gao JL, Wang L. Short-term weight loss decreased the risk of chronic kidney disease in men with incident non-alcoholic fatty liver disease. Obesity 2022, 30(7):1495-1506

4.    Yuan XJ, Wang XM, Wu SL, Chen SH, Wang YH, Wang JR, Lu Y, Sun YY, Fu QJ, Wang L. Associations Between Metabolic Dysfunction-Associated Fatty Liver Disease and Extrahepatic Cancers: A Cohort in China. Hepatobiliary Surg Nutrition 2022, https://dx.doi.org/10.21037/hbsn-21-546

5.    胡诗琪，蓝彦琦，吴寿岭，王晓墨，陈朔华，汪国栋，王丽. 肥胖及其变化对中国华北新发NAFLD成年男性患者心血管疾病发病风险的影响[J]. 基础医学与临床, 2022, 42(5): 788-794.

6.    Peng HX, Wang SY, Wang MY, Ye Y, Xue E, Chen X, Wang XH, Fan M, Gao WJ, Qin XY, Wu YQ, Chen DF, Li J, Hu YH, Wang L*, Wu T*. Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study. Metabolism, 2022，https://doi.org/10.1016/j.metabol.2022.15522

7.    Sun YY, Chen SH, Zhao XY, Wang YH, Lan YQ, Jiang XZ, Gao X, Wu SL, Wang L. Adherence to the dietary approaches to stop hypertension diet and non-alcoholic fatty liver disease. Liver international. 2022, https://doi.org/10.1111/liv.15156

8.    Zhang D., Wu S., Lan Y., Chen S., Wang Y., Sun Y., Liao W., Wang L. Blood manganese and nonalcoholic fatty liver disease: a cohort-based case-control study. Chemosphere. 2022, 287: 132316.

9.   Wang X., Wu S., Yuan X., Chen S., Fu Q., Sun Y., Lan Y., Hu S., Wang Y., Lu Y., Qu S., and Wang L. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study. J Clin Endocrinol Metab. 2021, doi: 10.1210/clinem/dgab644.

10.  Wang ZY, Zhao XY, Chen SH, Wang YH, Cao LY, Liao W, Sun YY, Wang XM, Zheng Y, Wu SL, Wang L. Associations between Nonalcoholic fatty liver disease and cancers in a large cohort in China. Clin Gastroenterol Hepatol 2021,19(4): 788-796

11.  Lan Y, Wu S, Wang Y, Chen S, Liao W, Zhang X., Pan L., Jiang X., Zhang Y., Wang L. Association between blood copper and nonalcoholic fatty liver disease according to sex. Clin Nutr. 2021, 40: 2045-2052

12.  Li R, Lin X, Wang J, Wang X, Lu J, Liu Y., Cao Z., Ren S., Ma L., Jin Y., Zheng S., Hu Z, Wang L., Chen X. Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Ann Transl Med. 2021, 9: 1365

13. Wang X., Chen Y., Xu M., Cheng K., Liao W., Wang Y., Lu Y., Duan Z., Wang L. Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir. Expert Rev Gastroenterol Hepatol. 2021, 15: 1337-1344.

14.  Lan Y., Wang L. Reply-letter to the editor: copper deficiency and nonalcoholic fatty liver disease: the chicken or the egg? Clin Nutr. 2021, 40: 5445-5446.

15.  Cheng K., Chen Y., Wang X., Xu M., Liao W., Duan X., Zhao X., Sun Y., Duan Z., Wang L. Entecavir combined with interferon-alpha is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B. Cancer. 2021, doi: 10.1002/cncr.33949.

16. Li MM, Sun YY, Yang J, Martel Cd, Charvat H, Clifford GM, Vaccarella S, Wang L. Time trends and other sources of variation in Helicobacter pylori infection in mainland China: a systematic review and meta-analysis. Helicobacter 2020 25:e12729 DOI: 10.1111/hel.12729

17. Lei SY, Chen SH, Zhao XY, Zhang YM, Cheng KL, Zhang XH, Wang ZY, Sun YY, Wu SL, Wang L. Hepatitis B virus infection and diabetes mellitus: the Kailuan prospective cohort study in China. Hepatology international 2020 14：745-753 https://doi.org/10.1007/s12072-020-10086-2

18.  Zheng Y, Xue M, Cai Y, Liao SS, Yang H, Wang ZY, Wang XM, Zhang XG, Qian JM, Wang L. Hospitalizations for Peptic Ulcer Disease in China: current features and outcomes. J Gastroenterol Hepatol 2020, 35: 2122-2130 doi:10.1111/jgh.15119

19.  Zhao XY, Wang N, Sun YY, Zhu GL, Wang YH, Wang ZY, Zhang YM, Cheng KL, Wang GD, Wu SL, Wang L. Screen-detected gallstone disease and risk of liver and pancreatic cancer: The Kailuan Cohort Study. Liver Int 2020, 40:1744-1755. https://doi.org/10.1111/liv.14456

20.  Liu Y, Cu XH, Wang XM, Wang ZY, Wang YH, Zhang H, Wang L. Out-of-pocket payments and economic consequences from tuberculosis care in eastern China: income inequality. Infectious Dis Poverty 2020, 9:14 doi.org/10.1186/ s40249-020-0623-8

21. 王振宇, 陈朔华, 赵欣宇, 王艳红, 吴寿岭, 王丽. Cox及其拓展模型在基于队列的依时暴露因素效应估计中的应用.中华流行病学杂志. 2020, 41(6): 957-96

正在更新中...